ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 674

Altered Response to B Cell Receptor (BCR) Crosslinking in SLE: Correlation with Genetic Risk Variants Predicted to Impact BCR Signaling

Nan-Hua Chang1, Timothy Li2, Paul R. Fortin3, Dafna D. Gladman4, Carolina Landolt-Marticorena5, Jorge Sanchez-Guerrero6, Murray B. Urowitz7 and Joan E. Wither8, 1Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 2Genetics and developmental biology, Toronto Western Hospital, Toronto, ON, Canada, 3University of Laval, Quebec, QC, Canada, 4Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, Canada, 5Rheumatology, University Health Network, University of Toronto, Toronto, ON, Canada, 6UHN Toronto Western Hospital, Toronto, ON, Canada, 7Division of Rheumatology, University Health Network, University of Toronto, Toronto, ON, Canada, 81E420/Div of Rheumatology, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: B cells, signal transduction and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Altered B cell signaling has been proposed to play an important role in susceptibility to SLE.  In mice, genetic manipulations or polymorphisms that attenuate BCR signaling have been shown to lead to altered selection or survival of self-reactive lymphocytes whereas those that lead to enhanced BCR signaling can breach B cell anergy, with both types of defects reported in various murine models of SLE.  Most previous reports indicate that SLE B cells are hyper-responsive to BCR crosslinking.  However, these findings contrast with preliminary evidence suggesting that some of the genetic risk variants associated with SLE may lead to attenuated BCR signaling.  In this study we have examined the association between these risk variants and the altered B cell function observed in SLE.

Methods: Patients (N=44) satisfying at least 4 ACR criteria and (N=30) healthy age-matched controls without a family history of systemic autoimmune disease were recruited.  PBMC were isolated over a Ficoll gradient, rested for 1 hr at 37oC, and then stimulated for 2’ with media alone, or 2’ and 10’ with media containing 20 μg/ml of F(ab’)2 goat anti-human IgM.  Cells were stained with anti-CD19, -CD27, -IgD, -IgM, and -CD38, to permit gating on naïve mature B cells (CD19+CD27–IgD+CD38+) stratified based on their IgM cell surface expression and transitional B cells (CD19+CD27–IgD+CD38++IgMhi).  B cell signaling was examined by Phosflow using anti-pSyk (pY348), –pPLCγ2 (pY759) or -pERK1/2 (pT202/Y204) Ab following fixation and permeabilization.  SNP genotyping of subject DNA was performed using TaqMan assays specific for rs2618476 (BLK), rs10516487 (BANK-1), rs7829816 (LYN), and rs2476601 (PTPN22).

Results: There was an increased proportion of naïve B cells in SLE patients that had elevated basal levels of pSYK and pERK, suggesting prior activation in-vivo.  Following IgM crosslinking, the naïve B cells of SLE patients demonstrated significantly increased levels of p-SYK and trends to increased levels of p-PLCγ2 and p-ERK above basal levels as compared to controls.  This increased signaling was most marked in the IgMhi mature naïve and transitional B cell compartments of SLE patients.  There was no correlation between the basal levels of phosphorylated signaling molecules and any of the SNPs examined.  No association was seen between BLK or LYN SNPs and any of the phosphorylated signaling molecules following IgM crosslinking.  Consistent with attenuated BCR function there was a trend to decreased pPLCγ2 and significantly decreased pERK with the lupus-associated PTPN22 variant at 10’ following IgM crosslinking.  The lupus associated BANK-1 variant was associated with decreased pPLCγ2 at 2’.  To further explore the role of non-genetic factors in the B cell hyper-responsive phenotype, serial measurements of pSYK were performed. Significant variations between individual visits were seen in a subset of patients.

Conclusion:  No correlation was observed between increased B cell signaling and several of the genetic risk variants predicted to alter B cell receptor function in SLE.  It is likely that this phenotype arises from other genetic or non-genetic factors.


Disclosure:

N. H. Chang,
None;

T. Li,
None;

P. R. Fortin,
None;

D. D. Gladman,
None;

C. Landolt-Marticorena,
None;

J. Sanchez-Guerrero,
None;

M. B. Urowitz,
None;

J. E. Wither,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/altered-response-to-b-cell-receptor-bcr-crosslinking-in-sle-correlation-with-genetic-risk-variants-predicted-to-impact-bcr-signaling/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology